ArriVent BioPharma (AVBP) vs Corvus Pharmaceuticals (CRVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Corvus Pharmaceuticals (CRVS) has outperformed ArriVent BioPharma (AVBP) over the past year, gaining 51.5% versus a loss of 19.7%. Corvus Pharmaceuticals is the larger company by market cap ($858.9 million vs $823.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVBP | CRVS |
|---|---|---|
| Share price | $16.71 | $10.21 |
| Market cap | $823.93M | $858.87M |
| 1-day change | -1.07% | -1.92% |
| YTD return | -16.95% | +35.19% |
| 1-year return | -19.74% | +51.53% |
| 5-year return | — | +110.30% |
| EPS (TTM) | $-3.62 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.83 | $26.95 |
| 52-week low | $11.36 | $6.39 |
| Distance from 52-week high | -53.36% | -62.12% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +82.53% | +224.58% |
| Average volume | 908.55K | 986.04K |
| Shares outstanding | 49.31M | 84.12M |
| Employees | 77 | 37 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRVS has outperformed AVBP by 71.3 percentage points over the past year.
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 77 employees
About Corvus Pharmaceuticals
CRVS stock →Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
AVBP vs CRVS FAQ
Which is bigger, ArriVent BioPharma or Corvus Pharmaceuticals?
Corvus Pharmaceuticals (CRVS) is larger, with a market capitalization of $858.87M compared with $823.93M for ArriVent BioPharma (AVBP).
Which stock has performed better over the past year, AVBP or CRVS?
CRVS returned +51.53% over the past 12 months, compared with -19.74% for AVBP (price return, excluding dividends). Past performance does not predict future results.
Are ArriVent BioPharma and Corvus Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.